From the first launch to ongoing market access operational execution, IntegriChain solves some of the most complex and pressing challenges associated with drug commercialization. We deliver pharma’s only comprehensive data, consulting, and business process platform for market access departments, providing the strategy, data, applications, and infrastructure for therapy commercialization.
Solutions overview
IntegriChain delivers the pharmaceutical industry’s largest and only data and business process platform for therapy commercialization and access. Manufacturers rely on our analytics, applications, and managed services to power their operations and harness the value of their channel, patient and payer data.
View all products
IntegriChain provides a complete set of professional services for commercialization and market access execution–from life science strategy and operational consulting to implementation, integration, migrations, and analytics.
Services overview
We help all stakeholders in the pharmaceutical industry drive access with our relentless focus on unifying all of the critical business functions for therapy commercialization and access – contracts & pricing, gross-to-net, channel, and patient services – to unlock strategic payer, provider, pharmacy and patient access insights.
Learn more about our company
Learn more about joining our growing IntegriChain team of data scientists, market access experts, analysts, and consulting professionals – our culture, our purpose, our teams in the US and Pune. Check out our careers or keep in touch for future opportunities.
Careers overview
November 1, 2021
Philadelphia, PA, November 1, 2021 – IntegriChain, delivering Life Sciences’ only comprehensive data and business process platform for market access, today reached a significant business milestone with its 15th anniversary of operations. Founded in 2006 by aggregating channel data for Life Sciences manufacturers, today IntegriChain’s ICyte Platform is rapidly becoming the technology backbone for Market Access, delivering the data, applications, and business process infrastructure for patient access and therapy commercialization. With ICyte, Life Sciences innovators are digitalizing labor-intensive processes – freeing up their best talent to identify and resolve coverage and availability hurdles and to manage pricing and forecasting complexity.
Today, the world’s leading Life Sciences innovators rely on IntegriChain’s data, analytics, SaaS applications, managed services, and advisory expertise to maximize successful patient initiation and adherence to critical therapies. IntegriChain’s team of more than 550 professionals worldwide serves 19 of the top-20 Life Sciences manufacturers, supports nearly half of all first therapy launches by emerging manufacturers, and manages 73% of industry channel data on the ICyte Platform.
“We are so very proud of the incredible growth and longevity of our company and team over the last 15 years,” said Kevin Leininger, CEO of IntegriChain. “Today ICyte is rapidly becoming the go-to technology platform for Life Sciences leaders and innovators of all types and sizes. We attribute our great success to continuous collaboration with our customers to improve and expand our technology, solutions, and services for Market Access and to the hundreds of outstanding professionals on our expanding team. We look forward to continuing to innovate and deliver world-class solutions to Market Access teams during our next stage of growth and evolution.”
IntegriChain Milestones IntegriChain was founded by Leininger and Executive Vice President Josh Halpern in November 2006 and launched its data aggregation platform in early 2007 and its cloud offerings in 2010. In 2015, the company relocated its headquarters to Center City Philadelphia to tap into the city’s rapidly growing healthcare tech human capital market and culture. In early 2016, IntegriChain announced a strategic equity partnership with Accel-KKR, the first tier-one investment in a Philadelphia healthcare tech company by a leading Silicon Valley private equity provider. Soon after, the company launched its Contracts & Pricing managed services offerings followed by the launch of its patient data products, Advisory practice, and gross-to-net applications and managed services. Since 2017, IntegriChain has acquired four complementary technology and managed services companies–the most recent of which was Cumberland Life Sciences–expanding its reach to the full breadth of Market Access. Today, IntegriChain is the leader in Contracts & Pricing managed services, increasingly serving upmarket Life Sciences manufacturers, and is focused on delivering its first and only unified Market Access platform serving the needs of Life Sciences commercial, operational, and finance teams.
About IntegriChain IntegriChain is Life Sciences’ data and application backbone for patient access and therapy commercialization. More than 250 manufacturers rely on IntegriChain’s ICyte Platform to orchestrate commercial and government payer contracting, patient services, and distribution channels. ICyte is the first and only platform that unites the financial, operational, and commercial data sets required to support therapy access in the era of specialty and precision medicine. With ICyte, Life Sciences innovators are digitalizing labor-intensive processes – freeing up their best talent to identify and resolve coverage and availability hurdles and to manage pricing and forecasting complexity. IntegriChain is backed by Accel-KKR, a leading Silicon Valley technology private equity firm. The company is headquartered in Philadelphia, PA, with offices in Ambler, PA; Raleigh, NC, and Pune, India. For more information, visit www.integrichain.com, or follow us on Twitter @IntegriChain and LinkedIn.
Contact Jennifer Guinan, Sage Strategic Marketing, 610.410.8111, Jennifer@sagestrat.com
Save the date!
Webinars & Resources
See List
